In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews (2/04)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Rediscovering Existing Drugs, features profiles of Ascend Therapeutics Inc., Ocularis Pharma Inc. and Oriel Therapeutics Inc. Plus these Start-Ups Across Health Care: Exagen Diagnostics Inc., Piedmont Pharmaceuticals LLC, Protein Forest Inc., Proteus Biomedical Inc. and Xilas Medical Inc.

You may also be interested in...



US Regulatory Roundup – September 2022: Philips Troubles, Software And User Fees

The ten most popular stories about US regulatory issues published by Medtech Insight last month were a mixed bag, with a Philips recall taking the top spot and stories about AI, user fees, and more adding to the list.

Execs On The Move: Dentsply Gets New CEO And CFO

An interactive view of medtech executive changes from the month of September 2022. Major changes include Dentsply's appointment of a new CEO and CFO, a new CTO at Accuray and a re-shuffle at Pulse Biosciences.

PacBio Unveils TRGT, A Tool For Characterizing Rare Disease

PacBio's TRGT can sequence broader sections of DNA, giving scientists and clinicians better odds of spotting repeated sections of DNA linked to disease.

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV002289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel